13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q3 2024 · Filed November 13, 2024 · Accession 0000950123-24-011277
Total Value
$498.7M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | ACLX | 2,346,630 | $196.0M | 39.29% |
| 2 | Zenas BioPharma, Inc | ZBIO | 4,911,539 | $83.1M | 16.66% |
| 3 | ARS Pharmaceuticals, Inc. | SPRY | 4,012,903 | $58.2M | 11.67% |
| 4 | CRISPR Therapeutics AG | CRSP | 1,048,951 | $49.3M | 9.88% |
| 5 | Design Therapeutics, Inc. | DSGN | 6,526,476 | $35.1M | 7.04% |
| 6 | Mineralys Therapeutics Inc. | MLYS | 2,016,822 | $24.4M | 4.90% |
| 7 | Alumis Inc. | ALMS | 1,959,896 | $20.9M | 4.20% |
| 8 | Nkarta, Inc. | NKTX | 3,333,333 | $15.1M | 3.02% |
| 9 | Oruka Therapeutics, Inc | ORKA | 375,330 | $9.2M | 1.84% |
| 10 | enGene Holdings Inc. | ENGNW | 747,750 | $4.9M | 0.99% |
| 11 | KALA Bio, Inc. | KALA | 443,661 | $2.5M | 0.51% |